Mark Henry Saunders

Title: Mark Henry Saunders: Innovator in Pharmaceutical Chemistry

Introduction

Mark Henry Saunders is a notable inventor based in Reading, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as inhibitors for various biological pathways.

Latest Patents

One of his key inventions is a patent for a 6-pyrimidin-isoindole derivative as an ERK1/2 inhibitor. This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide. The patent details novel physical forms of the compound, a process for preparing it, synthetic intermediates for use in the process, and novel formulations containing the compound, as well as its therapeutic uses.

Career Highlights

Mark Henry Saunders is currently associated with Otsuka Pharmaceutical Company, Limited, where he continues to innovate and contribute to the pharmaceutical industry. His work focuses on developing new therapeutic agents that can have a significant impact on patient care.

Collaborations

He has collaborated with notable colleagues such as Michael Reader and Nicola Elizabeth Wilsher, enhancing the research and development efforts within his team.

Conclusion

Mark Henry Saunders is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable innovations. His contributions, particularly in the area of ERK1/2 inhibitors, demonstrate his commitment to advancing medical science and improving therapeutic options.